Identification

Name
Ixazomib
Accession Number
DB09570
Type
Small Molecule
Groups
Approved, Investigational
Description

Ixazomib a second generation proteasome inhibitor (PI) and the first oral PI approved by the FDA in November 2015 for multiple myeloma treatment in combination with 2 other therapies (lenalidomide and dexamethasone) for patients who have received at least 1 prior therapy. It was found to have similar efficacy to bortezomib (the first PI approved for multiple myeloma therapy) in the control of myeloma growth and prevention of bone loss. Ixazomib citrate is marketed by Takeda Pharmaceuticals under the brand name Ninlaro, which is a prodrug that becomes quickly converted to its active metabolite, ixazomib, after administration.

Structure
Thumb
Synonyms
Not Available
External IDs
MLN 2238 / MLN2238 / MLN9708
Product Ingredients
IngredientUNIICASInChI Key
Ixazomib citrate46CWK97Z3K1239908-20-3MBOMYENWWXQSNW-AWEZNQCLSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
NinlaroCapsule4 mg/1OralMillennium Pharmaceuticals, Inc.2015-11-20Not applicableUs
NinlaroCapsule2.3 mgOralTakeda2016-09-21Not applicableCanada
NinlaroCapsule2.3 mg/1OralMillennium Pharmaceuticals, Inc.2015-11-20Not applicableUs
NinlaroCapsule4 mgOralTakeda2016-09-21Not applicableCanada
NinlaroCapsule3 mg/1OralMillennium Pharmaceuticals, Inc.2015-11-20Not applicableUs
NinlaroCapsule3 mgOralTakeda2016-09-21Not applicableCanada
Categories
UNII
71050168A2
CAS number
1072833-77-2
Weight
Average: 361.03
Monoisotopic: 360.081492
Chemical Formula
C14H19BCl2N2O4
InChI Key
MXAYKZJJDUDWDS-LBPRGKRZSA-N
InChI
InChI=1S/C14H19BCl2N2O4/c1-8(2)5-12(15(22)23)19-13(20)7-18-14(21)10-6-9(16)3-4-11(10)17/h3-4,6,8,12,22-23H,5,7H2,1-2H3,(H,18,21)(H,19,20)/t12-/m0/s1
IUPAC Name
2-{[(2,5-dichlorophenyl)(hydroxy)methylidene]amino}-N-[(1R)-1-(dihydroxyboranyl)-3-methylbutyl]ethanimidic acid
SMILES
[H][C@@](CC(C)C)(N=C(O)CN=C(O)C1=C(Cl)C=CC(Cl)=C1)B(O)O

Pharmacology

Indication

Ixazomib is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.

Associated Conditions
Pharmacodynamics

In vitro studies have shown ixazomib to induce apoptosis in multiple myeloma cells sensitive or resistant to other conventional therapies. In mouse xenograft models, ixazomib induced tumor growth inhibition.

Mechanism of action

Ixazomib is an N-capped dipeptidyl leucine boronic acid which reversibly inhibits the CT-L proteolytic (β5) site of the 20S proteasome. At higher concentrations, ixazomib also seems to inhibit the proteolytic β1 and β2 subunits and to induce accumulation of ubiquitinated proteins.

Absorption

After oral administration, the time to reach maximum concentration in plasma was 1 hour. The mean absolute oral bioavailability is 58%.

Volume of distribution

The steady-state volume of distribution is 543 L.

Protein binding

99%

Metabolism

Metabolism of ixazomib is expected to be by CYP and non-CYP pathways, with no predominant CYP isozyme contribution. At higher than clinical concentrations, ixazomib was metabolized by multiple CYP isoforms with estimated relative contributions of 3A4 (42%), 1A2 (26%), 2B6 (16%), 2C8 (6%), 2D6 (5%), 2C19 (5%) and 2C9 (<1%).

Route of elimination

62% in urine and 22% in feces.

Half life

Terminal half-life is 9.5 days.

Clearance
Not Available
Toxicity

Drug-induced liver injury, hepatocellular injury, hepatic steatosis, hepatitis cholestatic and hepatotoxicity have each been reported in <1% of patients. Ixazomib can cause fetal harm when administered to pregnant women, and therefore it should also be advised to women of reproductive age to avoid becoming pregnant on ixazomib.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
(R)-warfarinThe metabolism of Ixazomib can be decreased when combined with (R)-warfarin.
(S)-WarfarinThe metabolism of (S)-Warfarin can be decreased when combined with Ixazomib.
3,5-diiodothyropropionic acidThe metabolism of 3,5-diiodothyropropionic acid can be decreased when combined with Ixazomib.
4-hydroxycoumarinThe metabolism of 4-hydroxycoumarin can be decreased when combined with Ixazomib.
4-MethoxyamphetamineThe metabolism of Ixazomib can be decreased when combined with 4-Methoxyamphetamine.
5-androstenedioneThe metabolism of Ixazomib can be decreased when combined with 5-androstenedione.
6-Deoxyerythronolide BThe metabolism of Ixazomib can be decreased when combined with 6-Deoxyerythronolide B.
6-O-benzylguanineThe metabolism of 6-O-benzylguanine can be decreased when combined with Ixazomib.
AbacavirAbacavir may decrease the excretion rate of Ixazomib which could result in a higher serum level.
AbemaciclibThe metabolism of Abemaciclib can be decreased when combined with Ixazomib.
Food Interactions
  • A food effect study conducted in patients with a single 4 mg dose of ixazomib showed that a high-fat meal decreased ixazomib AUC by 28% and Cmax by 69%.

References

General References
  1. Offidani M, Corvatta L, Caraffa P, Gentili S, Maracci L, Leoni P: An evidence-based review of ixazomib citrate and its potential in the treatment of newly diagnosed multiple myeloma. Onco Targets Ther. 2014 Sep 29;7:1793-800. doi: 10.2147/OTT.S49187. eCollection 2014. [PubMed:25302026]
  2. Gentile M, Offidani M, Vigna E, Corvatta L, Recchia AG, Morabito L, Morabito F, Gentili S: Ixazomib for the treatment of multiple myeloma. Expert Opin Investig Drugs. 2015;24(9):1287-98. doi: 10.1517/13543784.2015.1065250. Epub 2015 Jul 3. [PubMed:26138345]
External Links
KEGG Drug
D10130
PubChem Compound
25183872
PubChem Substance
310265228
ChemSpider
25027391
BindingDB
50398609
ChEBI
90942
ChEMBL
CHEMBL2141296
HET
6V8
Drugs.com
Drugs.com Drug Page
Wikipedia
Ixazomib
ATC Codes
L01XX50 — Ixazomib
AHFS Codes
  • 10:00.00 — Antineoplastic Agents
PDB Entries
5lf7
FDA label
Download (463 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedBasic ScienceGlioblastomas1
1Active Not RecruitingTreatmentAdvanced Cancers1
1Active Not RecruitingTreatmentAdvanced Solid Tumors / Malignant Lymphomas1
1Active Not RecruitingTreatmentHigh Risk Smoldering Multiple Myeloma / Multiple Myeloma (MM)1
1Active Not RecruitingTreatmentLight-Chain Amyloidosis1
1Active Not RecruitingTreatmentRecurrent Adult Acute Myeloid Leukemia / Refractory Acute Myeloid Leukemia1
1CompletedTreatmentAdvanced Non-Hematologic Malignancies1
1CompletedTreatmentAdvanced Solid Tumors / Malignancies, Hematologic1
1CompletedTreatmentAdvanced Solid Tumors / Multiple Myeloma (MM)1
1CompletedTreatmentMalignant Lymphomas1
1CompletedTreatmentMalignant Lymphomas / Nonhematologic Malignancies1
1CompletedTreatmentMultiple Myeloma (MM)2
1CompletedTreatmentRelapsed and Refractory Multiple Myeloma1
1RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / B-cell Adult Acute Lymphoblastic Leukemia / Lymphoma, Lymphoblastic / T-cell Adult Acute Lymphoblastic Leukemia1
1RecruitingTreatmentAmyloid Light Chain (AL) Amyloidosis / Hematopoietic/Lymphoid Cancer1
1RecruitingTreatmentCancer, Breast1
1RecruitingTreatmentCastration-Resistant Prostate Carcinoma / Leukemia, Plasma Cell / Prostate Carcinoma Metastatic in the Bone / Recurrent Plasma Cell Myeloma / Stage IV Prostate Cancer1
1RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML)1
1RecruitingTreatmentMultiple Myeloma (MM) / Relapsed and/or Refractory Multiple Myeloma1
1RecruitingTreatmentTumors, Solid1
1TerminatedTreatmentMixed Phenotype Acute Leukemia (MPAL) / Relapsed or Refractory Acute Lymphoblastic Leukemia / Relapsed or Refractory Lymphoblastic Lymphoma1
1TerminatedTreatmentNephritis, Lupus1
1WithdrawnTreatmentAcute Lymphoblastic Leukemia in Complete Remission / Lymphoblastic Lymphoma in Complete Remission / Mixed Phenotype Acute Leukemia in Complete Remission1
1WithdrawnTreatmentMalignant Lymphomas / Neoplasms1
1, 2Active Not RecruitingTreatmentBladder Cancers1
1, 2Active Not RecruitingTreatmentKahler Disease / Multiple Myeloma (MM) / Myeloma, Plasma-Cell / Plasma Cell Myeloma1
1, 2Active Not RecruitingTreatmentMultiple Myeloma (MM)1
1, 2Active Not RecruitingTreatmentPatients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation1
1, 2Active Not RecruitingTreatmentRecurrent Plasma Cell Myeloma / Refractory Plasma Cell Myeloma1
1, 2CompletedTreatmentMultiple Myeloma (MM)3
1, 2RecruitingTreatmentAdult Burkitt Lymphoma / B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma / Lymphoma, Large B-Cell, Diffuse (DLBCL) / MYC Gene Mutation / Plasmablastic Lymphoma1
1, 2RecruitingTreatmentAmyloidosis / Plasma Cell Myeloma1
1, 2RecruitingTreatmentHematopoietic Stem Cell Transplantation (HSCT) / Multiple Myeloma (MM)1
1, 2RecruitingTreatmentHuman Immunodeficiency Virus (HIV)1
1, 2RecruitingTreatmentLymphoma, B Cell / Malignant Lymphomas1
1, 2RecruitingTreatmentLymphoma, T-Cell, Peripheral1
1, 2RecruitingTreatmentMantle Cell Lymphoma (MCL)2
1, 2RecruitingTreatmentMultiple Myeloma (MM)1
1, 2RecruitingTreatmentMultiple Myeloma in Relapse1
1, 2RecruitingTreatmentPlasma Cell Myeloma1
1, 2RecruitingTreatmentRecurrent Plasma Cell Myeloma / T(11;14)1
1, 2RecruitingTreatmentTriple-Negative Breast Cancer (TNBC)1
1, 2SuspendedTreatmentLoss of Chromosome 17p / Recurrent Plasma Cell Myeloma1
1, 2TerminatedTreatmentMetastatic Renal Cell Carcinoma / RCC1
2Active Not RecruitingPreventionChronic Leukemias / Leukemia, Acute / Malignant Lymphomas / Multiple Myeloma (MM) / Myelodysplastic Syndrome1
2Active Not RecruitingTreatmentMultiple Myeloma (MM)4
2Active Not RecruitingTreatmentNewly Diagnosed Multiple Myeloma1
2Active Not RecruitingTreatmentPlasma Cell Myeloma1
2Active Not RecruitingTreatmentWaldenström's Macroglobulinemia (WM)1
2CompletedTreatmentChronic Graft Versus Host Disease1
2CompletedTreatmentFollicular Lymphoma (FL)1
2CompletedTreatmentMultiple Myeloma (MM)1
2CompletedTreatmentT-Cell Lymphomas1
2Not Yet RecruitingTreatmentGenetic Condition / Multiple Myeloma (MM) / Relapsed and Refractory Multiple Myeloma1
2Not Yet RecruitingTreatmentHigh Risk / Newly Diagnosed / Plasma Cell Myeloma1
2Not Yet RecruitingTreatmentMantle Cell Lymphoma (MCL)1
2Not Yet RecruitingTreatmentMultiple Myeloma (MM)2
2RecruitingTreatmentAL Amyloidosis1
2RecruitingTreatmentAmyloidosis / Malignant Lymphomas / Multiple Myeloma (MM)1
2RecruitingTreatmentB-cell Non-Hodgkin's Lymphomas / Chronic Lymphocytic Leukaemia (CLL) / Follicular Lymphoma (FL) / Lymphoplasmacytic Lymphoma / Mantle Cell Lymphoma (MCL) / Marginal Zone Lymphoma / Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue / Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue / Small Lymphocytic Lymphoma (SLL) / Waldenström's Macroglobulinemia (WM)1
2RecruitingTreatmentEnd Stage Renal Disease (ESRD) / Kidney Diseases1
2RecruitingTreatmentKidney Medullary Carcinoma / Stage III Renal Cell Cancer AJCC v8 / Stage IV Renal Cell Cancer AJCC v81
2RecruitingTreatmentLeukemia, Plasma Cell / Plasma Cell Myeloma / Plasmacytoma1
2RecruitingTreatmentLymphoid Hematologic Malignancy / Myeloid Hematologic Malignancy1
2RecruitingTreatmentMultiple Myeloma (MM)7
2RecruitingTreatmentPlasmacytoma / POEMS Syndrome1
2RecruitingTreatmentPlasma Cell Myeloma1
2RecruitingTreatmentPlasma Cell Myeloma / Residual Disease1
2RecruitingTreatmentPlasma Cell Myeloma / Transplant-Related Carcinoma1
2RecruitingTreatmentRecurrent Plasma Cell Myeloma1
2RecruitingTreatmentRecurrent Plasma Cell Myeloma / Refractory Plasma Cell Myeloma4
2RecruitingTreatmentRecurrent Waldenstrom Macroglobulinemia / Refractory Waldenstrom Macroglobulinemia1
2RecruitingTreatmentRelapsed/Refractory Multiple Myeloma1
2RecruitingTreatmentSmoldering Multiple Myeloma (SMM)1
2TerminatedTreatmentAdult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Recurrent Adult Acute Myeloid Leukemia1
2TerminatedTreatmentLeukemias1
2WithdrawnTreatmentMultiple Myeloma (MM)2
2, 3RecruitingTreatmentRelapsed and/or Refractory Multiple Myeloma1
3Active Not RecruitingTreatmentAutologous Stem Cell Transplant / Multiple Myeloma (MM)1
3Active Not RecruitingTreatmentMultiple Myeloma (MM)1
3Active Not RecruitingTreatmentRefractory Multiple Myeloma / Relapsed Multiple Myeloma1
3CompletedTreatmentMultiple Myeloma (MM)1
3Not Yet RecruitingTreatmentMultiple Myeloma (MM)2
3RecruitingTreatmentMultiple Myeloma (MM)1
3RecruitingTreatmentRelapsed or Refractory Systemic Light Chain Amyloidosis1
3RecruitingTreatmentSolitary Osseous Plasmacytoma1
4RecruitingTreatmentMultiple Myeloma (MM)1
4RecruitingTreatmentRelapsed and/or Refractory Multiple Myeloma1
Not AvailableActive Not RecruitingNot AvailableRelapsed/Refractory Multiple Myeloma1
Not AvailableRecruitingNot AvailableRelapsed and/or Refractory Multiple Myeloma1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
CapsuleOral2.3 mg
CapsuleOral2.3 mg/1
CapsuleOral3 mg
CapsuleOral3 mg/1
CapsuleOral4 mg/1
CapsuleOral4 mg
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US8871745No2014-10-282027-08-06Us
US8530694No2013-09-102027-08-06Us
US7442830No2008-10-282027-08-06Us
US9175017No2015-11-032029-06-16Us
US8003819No2011-08-232027-08-06Us
US9233115No2016-01-122024-08-12Us
US8546608No2013-10-012024-08-12Us
US7687662No2010-03-302027-08-06Us
US8859504No2014-10-142029-06-16Us

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0179 mg/mLALOGPS
logP2.82ALOGPS
logP4.27ChemAxon
logS-4.3ALOGPS
pKa (Strongest Acidic)3.47ChemAxon
pKa (Strongest Basic)1.63ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area105.64 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity85.6 m3·mol-1ChemAxon
Polarizability36.45 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as hippuric acids and derivatives. These are compounds containing a hippuric acid or a derivative, with a structure characterized the presence of a benzoyl group linked to the N-terminal of a glycine.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzoic acids and derivatives
Direct Parent
Hippuric acids and derivatives
Alternative Parents
N-acyl-alpha amino acids and derivatives / Alpha amino acid amides / 2-halobenzoic acids and derivatives / 3-halobenzoic acids and derivatives / Benzoyl derivatives / Dichlorobenzenes / Aryl chlorides / Vinylogous halides / Secondary carboxylic acid amides / Boronic acids
show 8 more
Substituents
Hippuric acid or derivatives / N-acyl-alpha amino acid or derivatives / Alpha-amino acid amide / N-substituted-alpha-amino acid / Alpha-amino acid or derivatives / 2-halobenzoic acid or derivatives / 3-halobenzoic acid or derivatives / Halobenzoic acid or derivatives / 1,4-dichlorobenzene / Benzoyl
show 26 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Gupta N, Diderichsen PM, Hanley MJ, Berg D, van de Velde H, Harvey RD, Venkatakrishnan K: Population Pharmacokinetic Analysis of Ixazomib, an Oral Proteasome Inhibitor, Including Data from the Phase III TOURMALINE-MM1 Study to Inform Labelling. Clin Pharmacokinet. 2017 Nov;56(11):1355-1368. doi: 10.1007/s40262-017-0526-4. [PubMed:28290121]
  2. Kumar SK, Buadi FK, LaPlant B, Halvorson A, Leung N, Kapoor P, Dingli D, Gertz MA, Go RS, Bergsagel PL, Lin Y, Dispenzieri A, Hwa YL, Fonder A, Hobbs M, Fonseca R, Hayman SR, Stewart AK, Lust JA, Mikhael J, Gonsalves W, Reeder C, Skacel T, Rajkumar SV, Lacy MQ: Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. Blood Cancer J. 2018 Jul 30;8(8):70. doi: 10.1038/s41408-018-0106-3. [PubMed:30061664]
  3. Ixazomib FDA label [File]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2B6
Uniprot ID
P20813
Uniprot Name
Cytochrome P450 2B6
Molecular Weight
56277.81 Da
References
  1. Ixazomib EMA Label [File]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. EMA Label [File]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Ixazomib FDA Label [File]

Drug created on November 30, 2015 12:10 / Updated on November 17, 2018 04:48